biotech · Atopic Dermatitis · Moderate to Severe Atopic Dermatitis · KYMR
Kymera Therapeutics
Kymera Therapeutics clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 500 North Beacon Street, 4th Floor, Watertown, MA 02472, US
- Founded
- 2016
- Employees
- 289
- Programs
- 12
- Drugs
- 6
- Patents
- 29
Kymera Therapeutics projects
6 ClinicalTrials.gov programs sponsored by Kymera Therapeutics.
Kymera Therapeutics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
KT-621
Kymera Therapeutics
Atopic Dermatitis
2 trials -
KT-621
Kymera Therapeutics
Eosinophilic Asthma
1 trial -
KT621-AD-201
Kymera Therapeutics
Moderate to Severe Atopic Dermatitis
1 trial -
KT621-AS-202
Kymera Therapeutics
Uncontrolled Moderate to Severe Eosinophilic Asthma
1 trial -
SAR444656 (KT-474)
Kymera Therapeutics
Atopic Dermatitis
1 trial -
SAR444656 (KT-474)
Kymera Therapeutics
Hidradenitis Suppurativa
1 trial
Frequently asked questions
How many clinical projects does Kymera Therapeutics have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.